Lexicon Pharmaceuticals Announces Data On Early Clinical Benefit For INPEFA Will Be Among Five Lexicon-Sponsored Presentations At The American Heart Association Scientific Sessions 2023
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals (NASDAQ:LXRX) announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023. The presentations will highlight the early clinical benefit of INPEFA for heart failure and atherosclerotic events, and the cost-effectiveness metrics associated with the use of INPEFA. The FDA recently approved INPEFA for the treatment of heart failure.
November 02, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals' presentations at the American Heart Association Scientific Sessions 2023 could potentially boost investor confidence in the company's INPEFA product, which has recently been approved by the FDA for the treatment of heart failure.
The presentations at the American Heart Association Scientific Sessions 2023 will highlight the early clinical benefits and cost-effectiveness of INPEFA, which could potentially boost investor confidence in the product and the company. Furthermore, the recent FDA approval for INPEFA's use in treating heart failure adds to the product's credibility and potential market success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100